Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analyst consensus is “Hold” for Verrica Pharmaceuticals, based on five analysts: three buys, one hold, and one sell. The average 12-month price target is $12.67, compared with the stock’s recent opening price of $4.91.
• VRCA shares have traded between $3.28 and $9.82 over the past year, with a market capitalization of approximately $84.35 million and negative earnings.
• Institutional investors own 42.45% of the company, with several hedge funds recently establishing or increasing positions. Verrica is developing topical dermatology treatments, including the investigational products VP-102 and VP-103.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been assigned an average recommendation of "Hold" from the five analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $12.6667.

VRCA has been the subject of several recent research reports. Lake Street Capital assumed coverage on Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a "buy" rating and a $9.00 price target for the company. Wall Street Zen cut shares of Verrica Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Weiss Ratings reissued a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Finally, HC Wainwright initiated coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They set a "buy" rating and a $12.00 price target for the company.

Verrica Pharmaceuticals Stock Performance

Shares of Verrica Pharmaceuticals stock opened at $4.91 on Monday. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The business has a 50-day moving average price of $5.35 and a 200-day moving average price of $5.76. The firm has a market cap of $84.35 million, a price-to-earnings ratio of -2.94 and a beta of 1.49.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several hedge funds have recently bought and sold shares of VRCA. Affinity Asset Advisors LLC purchased a new stake in Verrica Pharmaceuticals in the 4th quarter valued at about $5,878,000. Armistice Capital LLC grew its holdings in Verrica Pharmaceuticals by 75.1% during the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company's stock worth $9,298,000 after acquiring an additional 479,732 shares in the last quarter. Velan Capital Investment Management LP bought a new position in Verrica Pharmaceuticals during the 4th quarter worth about $3,919,000. Boothbay Fund Management LLC purchased a new position in Verrica Pharmaceuticals during the 3rd quarter valued at about $1,210,000. Finally, Kalehua Capital Management LLC bought a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $1,959,000. Institutional investors own 42.45% of the company's stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.